Defining benefit: Clinically and biologically meaningful outcomes in the next‐generation Alzheimer's disease clinical care pathway
Alzheimer's & Dementia · 2025-02 · 21 (2)
DOI: 10.1002/alz.14425 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia, online erschienen am 19.12.2024. Verfasst von Aya Elhage und 7 weiteren Autor:innen. Beteiligte Einrichtung: Eisai Inc., Nutley, New Jersey, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Outcome Assessment, Health Care, Precision Medicine. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institute on Aging (NIA), NIGMS NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
To understand the potential benefits of emerging Alzheimer's disease (AD) therapies within and beyond clinical trial settings, there is a need to advance current outcome measurements into meaningful information relevant to all stakeholders. The relationship between the impact on disease biology and clinically measurable outcomes in cognition, function, and behavior must be considered when defining the meaningful benefit of early AD therapies. In this review, we discuss: (1) the lack of consideration for biomarkers in the current concept of meaningfulness in AD; (2) the lack of gold standards for determining minimal biologically and clinically important differences (MBCIDs) in AD trials; (3) how the treatment benefits of disease‐modifying treatments are cumulative and increase over time; and (4) the different concepts of meaningfulness among key stakeholders. This review utilizes the future clinical biological framework of AD and aims to further integrate and expand the parameters of meaningful benefits toward a precision medicine framework. Highlights Definition of meaningful benefit from Alzheimer's disease (AD) treatment varies across disease stage and stakeholder perspectives. Observable and meaningful outcomes must consider the clinical‐biological nature of AD. Statistically significant effects or outcomes do not always equate to clinically meaningfulness. Assessment tools must reflect stage‐specific subtle changes following treatment. Real‐world evidence will support consensus, definition, and interpretation of clinical meaningfulness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eisai Inc., Nutley, New Jersey, USA.
- Toronto Memory Program, North York, ON, Canada.
- University of Nevada Las Vegas, Las Vegas, Nevada, USA.
- Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands.
- Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
ORCID-Profile: Harald Hampel
Förderung
- NIA NIH HHS
- National Institute on Aging (NIA)
- NIGMS NIH HHS
- Ted and Maria Quirk Endowment
- Alzheimer's Disease Drug Discovery Foundation
- Joy Chambers-Grundy Endowment
- Eisai Inc.
- National Institute of General Medical Sciences
Zitieren
APA
Elhage, A., Cohen, S., Cummings, J., van der Flier, W. M., Aisen, P., Cho, M., Bell, J., & Hampel, H. (2025). Defining benefit: Clinically and biologically meaningful outcomes in the next‐generation Alzheimer's disease clinical care pathway. Alzheimer's & Dementia, 21(2). https://doi.org/10.1002/alz.14425
Vancouver
Elhage A, Cohen S, Cummings J, van der Flier WM, Aisen P, Cho M, et al. Defining benefit: Clinically and biologically meaningful outcomes in the next‐generation Alzheimer's disease clinical care pathway. Alzheimer's & Dementia. 2025;21(2). doi:10.1002/alz.14425
BibTeX
@article{Elhage2025,
author = {Elhage, Aya and Cohen, Sharon and Cummings, Jeffrey and van der Flier, Wiesje M and Aisen, Paul and Cho, Min and Bell, Joanne and Hampel, Harald},
title = {Defining benefit: Clinically and biologically meaningful outcomes in the next‐generation Alzheimer's disease clinical care pathway},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {2},
doi = {10.1002/alz.14425}
}
EUVIMED